 The purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia CML or Philadelphia chromosome positive acute lymphoblastic leukemia Ph ALL who no longer can tolerate treatment with imatinib. The safety of the treatment will also be studied. 